Roivant Sciences Ltd. - 8-K Filing
Roivant announces positive results from PHocus trial for mosliciguat in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD), meeting primary and secondary endpoints. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $ROIV